RaySearch Laboratories gets FDA approval for RayStation 3.5

In March RaySearch Laboratories AB announced that version 3.5 of RaySearch's RayStation® treatment planning system had been released for clinical use. RaySearch has now received 510(k) clearance from the FDA for RayStation® 3.5 meaning that the new features can be marketed in the US.

The most important new features are state of-the-art tools for treatment planning of radiation therapy with electrons and protons, complementing RayStation's extensive tools for planning and optimization of radiation therapy with photons. Proton Beam Design is a brand new module in RayStation® that contains tools for treatment planning of double scattered and uniformly scanned protons, such as a clinically approved Pencil Beam dose engine and automatic generation of treat-and-protect beams. This is the first clinical release of proton planning functionality in RayStation®, to be followed by many others, such as Pencil Beam Scanning techniques and Monte Carlo dose calculations. Electron Beam Design is another entirely new module that includes a Monte Carlo dose engine for electron radiation therapy and tools for manual editing of beams similar to how it is done in the 3D-CRT module.

In addition the new version contains a wide range of other new features and improvements.

"We are of course happy that we now have a complete offering for our US customers, with support for all treatment modalities including protons and electrons, and support all IMRT and VMAT delivery modes with all relevant treatment machines. This new version also includes some highly useful tools to improve the clinical workflow and further expands our market-leading toolbox for adaptive 4D treatments, which I believe further cements RayStation's position as the most advanced treatment planning system on the US market", says Johan Löf, CEO of RaySearch.